Skip to Content

AstraZeneca Reports Slightly Lower Estimate of COVID-19 Vaccine Effectiveness

THURSDAY, March 25, 2021 -- Following a sharp rebuke from an independent oversight board over potentially misleading information on the effectiveness of its COVID-19 vaccine, AstraZeneca released new data late Wednesday that showed the vaccine is slightly less effective than the company claimed on Monday.

The pharmaceutical giant stressed that its vaccine is still very powerful at preventing infection with COVID-19, based on more recent data than were used when the company first announced the interim results of its U.S. clinical trial.

After saying that the vaccine was 79 percent effective on Monday, the company said Wednesday that the vaccine was 76 percent effective at preventing COVID-19.

"The [latest] primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over," Mene Pangalos, Ph.D., executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a company news release. "We look forward to filing our regulatory submission for Emergency Use Authorization in the U.S. and preparing for the rollout of millions of doses across America."

AstraZeneca Press Release

© 2021 HealthDay. All rights reserved.

Read this next

Vaccinating Lactating Mothers May Protect Infants From COVID-19

WEDNESDAY, April 21, 2021 -- Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are detectable in the breast milk of lactating women up to 80 days...

Mechanism ID'd for Thrombosis After ChAdOx1 nCoV-19 Vaccine

WEDNESDAY, April 21, 2021 -- A pathogenic platelet factor 4 (PF4)-dependent syndrome has been observed rarely after administration of the ChAdOx1 nCoV-19 vaccine, according to a...

Sex Disparities in COVID-19 Deaths Not Seen Across Race

WEDNESDAY, April 21, 2021 -- Sex disparities in COVID-19 mortality do not hold across racial groups, according to a study published online April 5 in the Journal of General...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.